Yu et al. [72] studied the action of melatonin toward the development of diabetes-related NAFLD and analyzed the underlying mechanisms of this process by inhibiting NLRP3 inflammasome activation. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.